Non-HDL Study Exposes Basic Lipid Panel Error Rates
|
By LabMedica International staff writers Posted on 09 Oct 2013 |
|
Image: ARCHITECT C-8000 automatic biochemistry system (Photo courtesy of Abbott).
Patients evaluated with the basic lipid panel may have significant errors in risk classification, especially when relying on low-density lipoprotein cholesterol (LDLc).
Differences between LDLc and non-high density lipoprotein cholesterol (NHDLc) levels are greatest when accurate measurement is most critical as in high-risk patients with low LDLc targets and high triglycerides.
Scientists at the Johns Hopkins Ciccarone Center (Baltimore, MD, USA) examined lipid profiles in more than 1.3 million adults from the Very Large Database of Lipids (VLDL) dataset from 2009 to 2011. This is a massive collection of blood lipid samples measured with vertical density gradient ultracentrifugation by the Vertical Auto Profile (VAP) Lipid Panel (Atherotech; Birmingham, AL, USA).
The collaborating scientists from Johns Hopkins and Atherotech showed that a significant percentage of patients were reclassified by NHDLc and moved into to a higher treatment category compared with LDLc. For patients with estimated LDLc levels below 70 mg/dL and triglycerides between 150 and 199 mg/dL, 22% had NHDLc levels at or above 100 mg/dL, and 50% had NHDLc levels above the 93 mg/dL level.
Triglycerides were directly measured using the Abbott ARCHITECT C-8000 system (Abbott Laboratories; Abbott Park, IL, USA). Several limitations, including inaccuracy with elevated triglycerides as low as 150mg/dL , make LDLc a less accurate marker of cardiovascular risk than secondary measures such as NHDLc, which has targets set at about 30 mg/dL above LDLc targets with no specific studies establishing validity.
Michael Cobble, MD, Atherotech’s Chief Medical Officer, said, “Non-HDL cholesterol targets probably need to be lowered to bring them more in line with LDLc targets. However, from a clinical perspective, the variation and underestimation of risk that occurs with estimated LDLc in high-risk patients is unacceptable. A direct measure of LDLc along with non-HDLc components, as provided by the VAP Lipid Panel, is more accurate, in fasting or non-fasting patients." The study was published on September 18, 2013, in the Journal of the American College of Cardiology.
Related Links:
Johns Hopkins Ciccarone Center
Atherotech
Abbott Laboratories
Differences between LDLc and non-high density lipoprotein cholesterol (NHDLc) levels are greatest when accurate measurement is most critical as in high-risk patients with low LDLc targets and high triglycerides.
Scientists at the Johns Hopkins Ciccarone Center (Baltimore, MD, USA) examined lipid profiles in more than 1.3 million adults from the Very Large Database of Lipids (VLDL) dataset from 2009 to 2011. This is a massive collection of blood lipid samples measured with vertical density gradient ultracentrifugation by the Vertical Auto Profile (VAP) Lipid Panel (Atherotech; Birmingham, AL, USA).
The collaborating scientists from Johns Hopkins and Atherotech showed that a significant percentage of patients were reclassified by NHDLc and moved into to a higher treatment category compared with LDLc. For patients with estimated LDLc levels below 70 mg/dL and triglycerides between 150 and 199 mg/dL, 22% had NHDLc levels at or above 100 mg/dL, and 50% had NHDLc levels above the 93 mg/dL level.
Triglycerides were directly measured using the Abbott ARCHITECT C-8000 system (Abbott Laboratories; Abbott Park, IL, USA). Several limitations, including inaccuracy with elevated triglycerides as low as 150mg/dL , make LDLc a less accurate marker of cardiovascular risk than secondary measures such as NHDLc, which has targets set at about 30 mg/dL above LDLc targets with no specific studies establishing validity.
Michael Cobble, MD, Atherotech’s Chief Medical Officer, said, “Non-HDL cholesterol targets probably need to be lowered to bring them more in line with LDLc targets. However, from a clinical perspective, the variation and underestimation of risk that occurs with estimated LDLc in high-risk patients is unacceptable. A direct measure of LDLc along with non-HDLc components, as provided by the VAP Lipid Panel, is more accurate, in fasting or non-fasting patients." The study was published on September 18, 2013, in the Journal of the American College of Cardiology.
Related Links:
Johns Hopkins Ciccarone Center
Atherotech
Abbott Laboratories
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Auto Clinical Chemistry Analyzer
cobas c 703
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
Novel Point-of-Care Technology Delivers Accurate HIV Results in Minutes
HIV diagnostic methods have traditionally relied on detecting HIV-specific antibodies, which typically appear weeks after infection. This delayed detection has hindered early diagnosis, complicating patient... Read more
Blood Test Rules Out Future Dementia Risk
Previous studies have suggested that specific biomarkers, such as tau217, Neurofilament Light (NfL), and Glial Fibrillary Acidic Protein (GFAP), may be valuable for early dementia diagnosis.... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read more
Pathology
view channel
AI Model Predicts Patient Response to Bladder Cancer Treatment
Each year in the United States, around 81,000 new cases of bladder cancer are diagnosed, leading to approximately 17,000 deaths annually. Muscle-invasive bladder cancer (MIBC) is a severe form of bladder... Read more
New Laser-Based Method to Accelerate Cancer Diagnosis
Researchers have developed a method to improve cancer diagnostics and other diseases. Collagen, a key structural protein, plays various roles in cell activity. A novel multidisciplinary study published... Read more
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreTechnology
view channel
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read moreIndustry
view channel
New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics
With the rise of global pandemics, antimicrobial resistance, and emerging pathogens, healthcare systems worldwide are increasingly dependent on advanced diagnostic tools to guide clinical decisions.... Read more
